Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06848348 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
A Phase 2 study of Chemotherapy Induced Neuropathic Pain, sponsored by Dogwood Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06848348 is a Phase 2 study of Chemotherapy Induced Neuropathic Pain that is actively recruiting participants, run by Dogwood Therapeutics. The registered enrollment target is 200 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT06848348, a Phase 2 study of Chemotherapy Induced Neuropathic Pain, is actively recruiting participants, sponsored by Dogwood Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
A randomized study to determine safety and efficacy of single subcutaneous (SC) administration of HAL treatment in patients with CINP.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Halneuron
Study Locations (20)
Florida
- Central Recruiting Site - Jacksonville
- Central Recruiting Site - Jacksonville
- Central Recruiting Site - Lakeland
- Central Recruiting Site - Orlando
- Central Recruiting Site - Port Charlotte
- Central Recruiting Site - Tampa
California
- Central Recruiting Site - Fair Oaks
- Central Recruiting Site - Fountain Valley
- Central Recruiting Site - Los Angeles
- Central Recruiting Site - Santa Rosa
Missouri
- Central Recruiting Site - Fenton
- Central Recruiting Site - Kansas City
Alabama
- Central Recruiting Site - Sheffield
Arizona
- Central Recruiting Site - Glendale
Colorado
- Central Recruiting Site - Wheat Ridge
Georgia
- Central Recruiting Site - Atlanta
Illinois
- Central Recruiting Site - Gurnee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-02-21 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06848348
The ClinicalTrials.gov registry entry for NCT06848348 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dogwood Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chemotherapy Induced Neuropathic Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06848348 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT06848348 about?
NCT06848348 is a clinical study titled "Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain". A randomized study to determine safety and efficacy of single subcutaneous (SC) administration of HAL treatment in patients with CINP.
What is the current status of trial NCT06848348?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-02-21. Estimated completion is 2026-08.
What conditions does trial NCT06848348 study?
This clinical trial studies the following conditions: Chemotherapy Induced Neuropathic Pain.
What interventions are being tested in trial NCT06848348?
The interventions under investigation include: Placebo (DRUG), Halneuron (DRUG).
Who is sponsoring clinical trial NCT06848348?
This trial is sponsored by Dogwood Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06848348 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.